Rallybio Corp (RLYB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rallybio Corp (RLYB) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.68 Million) by net assets ($57.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rallybio Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Rallybio Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Rallybio Corp for a breakdown of total debt and financial obligations.
Rallybio Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rallybio Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sheetal Cool Products Limited
NSE:SCPL
|
0.035x |
|
Nandan Denim Limited
NSE:NDL
|
0.071x |
|
Euro Yatirim Holding AS
IS:EUHOL
|
-0.480x |
|
Mad Paws Holdings Ltd
AU:MPA
|
0.133x |
|
Haoxi Health Technology Limited Class A Ordinary Shares
NASDAQ:HAO
|
-0.064x |
|
LTKM Bhd
KLSE:7085
|
0.094x |
|
Kocom Co. Ltd
KQ:015710
|
0.036x |
|
Minehub Technologies Inc
V:MHUB
|
-1.632x |
Annual Cash Flow Conversion Efficiency for Rallybio Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rallybio Corp from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Rallybio Corp.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.96 Million | $-29.81 Million | -0.514x | +35.65% |
| 2024-12-31 | $61.65 Million | $-49.28 Million | -0.799x | -40.84% |
| 2023-12-31 | $106.18 Million | $-60.27 Million | -0.568x | -67.75% |
| 2022-12-31 | $169.32 Million | $-57.28 Million | -0.338x | -30.48% |
| 2021-12-31 | $175.60 Million | $-45.53 Million | -0.259x | -60.01% |
| 2020-12-31 | $136.00 Million | $-22.04 Million | -0.162x | +81.82% |
| 2019-12-31 | $16.86 Million | $-15.03 Million | -0.891x | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more